Phase I/II study of HSCT from HLA-matched donor using post-transplant cyclophosphamide

Phase I/II study of HSCT from HLA-matched donor using post-transplant cyclophosphamide - Tsukuba PTCY for MRD/MUD

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000028779

Enrollment

Registered

2017-11-01

Start date

2017-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

AML, ALL, NHL. MDS

Interventions

50 mg/kg of cyclophosphamide on day 3, 4

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) AML, ALL, NHL, MDS 2) age 16-60 3) PS =< 2 4) EF >= 40% 5) SpO2 >= 90% 6) Bil =< 2.0 mg/dl 7) Ccr >= 30 ml/min

Exclusion criteria

Exclusion criteria: 1) positive for HBs Ag 2) positive for HIV Ag 3) depression 4) pregnancy 5) coexisting active cancer 6) active infection

Design outcomes

Primary

Measure	Time frame
Success rate at 6 months.	—

Countries

Japan

Contacts

Public ContactKurita Naok

University of Tsukuba Department of Hematology, Faculty of Medicine

kuripon@mvb.biglobe.ne.jp029-853-3127

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026